(Q36870068)

16 August 2017

1 reference

title

Off-label prescription of quetiapine in psychiatric disorders (English)

1 reference

16 August 2017

Donald L Rowe

1

1 reference

16 August 2017

publication date

1 July 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

841-852

1 reference

Higher levels of basal serial CSF cortisol in combat veterans with posttraumatic stress disorder

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Hypothalamic-pituitary-adrenal axis activity and sleep in posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Hypercortisolism associated with social subordinance or social isolation among wild baboons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Vascular depression: An archetypal neuropsychiatric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Is poststroke depression a vascular depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Post-stroke and vascular depression: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Poststroke depression and lesion location revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Do personality disorders predict negative treatment outcome in obsessive-compulsive disorders? A prospective 6-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine: efficacy, tolerability and safety in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine increases the firing rate of rat substantia nigra and ventral tegmental area dopamine neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine regulates the stress-induced increase in corticotropin-releasing factor mRNA expression in the rat hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine for the treatment of borderline personality disorder; an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Fluoxetine and impulsive aggressive behavior in personality-disordered subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Serotonin function and antiaggressive response to fluoxetine: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine in the treatment of borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Pharmacotherapy of post-traumatic stress disorder: a family practitioners guide to management of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Emerging roles for atypical antipsychotics in chronic post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine therapy for posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

A review of pharmacologic treatments for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine Addition in Obsessive-Compulsive Disorder: Is Treatment Outcome Affected by Type and Dose of Serotonin Reuptake Inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Summary of Guideline for the Treatment of Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Extending indications for long-term pharmacotherapy: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine as adjunctive treatment of a case of rapid-cycling bipolar disorder with comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine for treatment of alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine in bipolar disorder and cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Atypical antipsychotics in the treatment of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine augmentation of treatment-resistant depression: a comparison with lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine augmentation in treatment-resistant depression: a naturalistic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Possible hypothyroidism associated with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Priapism and quetiapine in an HIV-positive male

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine and leukopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Thrombotic thrombocytopenic purpura associated with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Twice-yearly exams unnecessary for patients taking quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Biomarkers in the diagnosis of Alzheimer's disease: are we ready?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Causal Heterogeneity in Attention-Deficit/Hyperactivity Disorder: Do We Need Neuropsychologically Impaired Subtypes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Different psychophysiological and behavioral responses elicited by frustration in pediatric bipolar disorder and severe mood dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Brain profiling and clinical-neuroscience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

21 January 2018

Integrative neuroscience

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Integrative neuroscience approach to predict ADHD stimulant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Attention-deficit/hyperactivity disorder: neurophysiology, information processing, arousal and drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Brain structure and function correlates of general and social cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Trauma and Hallucinatory Experience in Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

Quetiapine in combination with citalopram in patients with unipolar psychotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.841

21 January 2018

Identifiers

DOI

10.1586/14737175.7.7.841

1 reference

16 August 2017

1 reference